Odyssey Health Files Q3 2024 10-Q

TL;DR

Odyssey Health (OHGI) filed its 10-Q for April 2024. Check financials.

AI Summary

Odyssey Health, Inc. filed its quarterly report for the period ending April 30, 2024. The company, formerly known as Odyssey Group International, Inc., is based in Las Vegas, Nevada, and operates in the surgical and medical instruments sector. This filing covers the third quarter of their fiscal year, which ends on July 31st.

Why It Matters

This filing provides investors with an update on Odyssey Health's financial performance and operational status for the most recent quarter.

Risk Assessment

Risk Level: low — This is a standard 10-Q filing with no immediately apparent significant negative events or disclosures.

Key Players & Entities

• Odyssey Health, Inc. (company) — Filer of the 10-Q
• Odyssey Group International, Inc. (company) — Former name of Odyssey Health, Inc.
• 2024-04-30 (date) — End of the reporting period
• 2024-06-14 (date) — Date of filing
• 702-780-6559 (phone_number) — Business phone number

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock ($0.001 par value) ODYY OTC Indicate by che
• $1,000,000 — sets") to Oragenics in exchange for (i) $1,000,000 in cash; (ii) 8,000,000 shares of conve
• $325,672 — nd (iii) the assumption by Oragenics of $325,672 of our accounts payable. See Note 4. W
• $16,400,687 — tal value of consideration received was $16,400,687. The Assets include drug candidates fo
• $0.91 — f Oragenics common stock were valued at $0.91 per share based a discount to the closi
• $1.04 — ice of Oragenics common stock which was $1.04 per share at April 30, 2024, as quoted

Filing Documents

• odyssey_i10q-043024.htm (10-Q) — 741KB
• odyssey_ex3101.htm (EX-31.1) — 8KB
• odyssey_ex3102.htm (EX-31.2) — 8KB
• odyssey_ex3201.htm (EX-32.1) — 4KB
• odyssey_ex3202.htm (EX-32.2) — 4KB
• 0001683168-24-004251.txt ( ) — 4616KB
• odyy-20240430.xsd (EX-101.SCH) — 40KB
• odyy-20240430_cal.xml (EX-101.CAL) — 45KB
• odyy-20240430_def.xml (EX-101.DEF) — 173KB
• odyy-20240430_lab.xml (EX-101.LAB) — 334KB
• odyy-20240430_pre.xml (EX-101.PRE) — 294KB
• odyssey_i10q-043024_htm.xml (XML) — 551KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION Item 1

Financial Statements

Financial Statements 3 Condensed Consolidated Balance Sheets 3 Condensed Consolidated Statements of Operations 4 Condensed Consolidated Statements of Stockholders' Equity (Deficit) 5 Condensed Consolidated Statements of Cash Flows 6 Notes to Condensed Consolidated Financial Statements 7 Item 2

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 19 Item 3

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 25 Item 4

Controls and Procedures

Controls and Procedures 26

- OTHER INFORMATION

PART II - OTHER INFORMATION Item 1A

Risk Factors

Risk Factors 27 Item 5 Other Information 27 Item 6 Exhibits 27

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements Odyssey Health, Inc. Condensed Consolidated Balance Sheets (Unaudited) As of April 30, July 31, 2024 2023 Assets Current assets: Cash $ 66,014 $ 36,865 Research and development rebate due from the Australian government 22,625 276,566 Prepaid expenses and other current assets 64,764 92,457 Total current assets 153,403 405,888 Intangible assets, net of accumulated amortization of $ 0 and $ 5,376 – 49,905 Investments 13,422,474 – Total assets $ 13,575,877 $ 455,793 Liabilities and Stockholders' Deficit Current liabilities: Accounts payable $ 1,296,567 $ 1,797,656 Accrued wages 1,487,173 1,402,348 Accrued interest 187,013 142,032 Asset purchase liability 1,125,026 1,125,026 Notes payable, officers and directors 100,000 125,000 Notes payable, net of unamortized beneficial conversion feature, debt discount and closing costs of $ 84,123 and $ 280,340 1,500,544 2,019,660 Total current liabilities 5,696,323 6,611,722 Commitments and contingencies – – Stockholders' equity (deficit): Preferred stock, $ 0.001 par value, 100,000,000 shares authorized, no shares issued or outstanding – – Common stock, $ 0.001 par value, 500,000,000 shares authorized, 96,359,763 and 79,067,879 shares issued and outstanding as of April 30, 2024 and July 31, 2024, respectively 96,360 79,068 Additional paid-in-capital 56,046,834 53,862,378 Accumulated deficit ( 48,263,640 ) ( 60,097,375 ) Total stockholders' equity (deficit) 7,879,554 ( 6,155,929 ) Total liabilities and stockholders' equity $ 13,575,877 $ 455,793 The accompanying notes are an integral part of these condensed consolidated financial statements. 3 Odyssey Health, Inc. Condensed Consolidated Statements of Operations (Unaudited) For the Three Months Ended April 30, For the Nine Months Ended April 30, 2024 2023 2024 2023 In-process research and development expense $ – $ – $ – $ 170,000

View Full Filing

View this 10-Q filing on SEC EDGAR